Surrozen, Inc. Common

Day range

$24.97 – $27.75

Open

$25.23

Prev close

$25.48

Volume

192.91K

Market cap

$299.48M

Shares out

11.61M

P/E

—

P/S

26.02

P/B

-1.37

P/FCF

—

ROE

160.2%

ROA

-303.0%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionOct 20, 2026

  The Second Closing was contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration of the Company's Investigational New Drug Application for SZN-8141 ... On October 2, 2026, the Company announced that the Second Closing Milestone had been achieved.

• Regulatory decisionOct 2, 2026

  On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The IND went into effect following the completion of the statutory 30-day review period.

• Director departureJan 30, 2026

  On January 26, 2026, Shao-Lee Lin, M.D., Ph.D. resigned from the Board of Directors of Surrozen, Inc., or the Company, effective immediately. Dr. Lin's resignation was not because of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Executive officer departureNov 7, 2025

  In connection with Mr. Maleki's appointment as Chief Financial Officer, Charles Williams will cease to serve as the Company's Chief Financial Officer, but will continue to serve as the Company's Chief Operating Officer and Secretary.

• Partnership or collaborationOct 17, 2025

  Under the terms of the Collaboration Agreement, the Company provided antibody discovery services. TCGFB owned all TGF-β product related intellectual property. In exchange for the Company's research services, TCGFB agreed to pay the Company up to $6.0 million in the aggregate, plus any third-party costs, and issued the Company a warrant exercisable for up to 3.4 million shares of TCGFB common stock at an exercise price of $0.0001 per share based on certain vesting conditions.

Days to cover

1.5

Short interest

2.19M

Avg volume

1.45M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
  positiveGlobeNewswire Inc.· Oct 20, 2026
• Surrozen Reports Q2 Profit on Gains
  neutralThe Motley Fool· Aug 8, 2025
• Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
  GlobeNewswire Inc.· Jun 12, 2024
• Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
  GlobeNewswire Inc.· Jun 10, 2024
• Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
  GlobeNewswire Inc.· Jun 4, 2024